Pacific Biosciences (PACB) 8.28 $PACB Biotech S
Post# of 273258
Posted On: 09/02/2016 7:08:32 PM
Pacific Biosciences (PACB) 8.28 $PACB
Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 4.53 (-0.06), PACB: 8.28 (-0.02), BMRN: 95.73 (+0.54), ALXN: 123.67 (-1.96)
Pacific Biosciences (PACB) Q2 Impressive, View Encourages
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 6:45AM CDT
Pacific Biosciences of California Inc. (PACB) reported a loss of 21 cents per share, a penny narrower than the Zacks Consensus Estimate.
BABY: 40.64 (+0.93), PACB: 8.28 (-0.02), MASI: 59.90 (+0.47), MLAB: 112.17 (-1.21)
Pacific Biosciences Releases New Software and Chemistry for Sequel System
GlobeNewswire - Thu Aug 04, 3:14PM CDT
Pacific Biosciences of California, Inc. (Nasdaq
ACB) today announced it has released a set of key updates for the Sequel(TM) System, the company's latest product based on its Single Molecule, Real-Time (SMRT) Sequencing technology. The new release provides performance improvements via updated sequencing chemistry, optimized sample clean-up protocols, and associated software that together further improve read lengths, throughput and accuracy of the system. In addition, as customers upgrade their Sequel Systems to the new software and chemistry, they will no longer be subject to the supply constraints for SMRT Cells that were in effect earlier this year.
PACB: 8.28 (-0.02)
Pacific Biosciences of California, Inc. Announces Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:00PM CDT
Pacific Biosciences of California, Inc. (NASDAQACB) today announced financial results for its second quarter ended June 30, 2016.
PACB: 8.28 (-0.02)
Pacific Biosciences (PACB) Q2 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:52AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 51.26 (+0.15), PACB: 8.28 (-0.02), ANIP: 59.86 (-1.56), GLYC: 7.25 (-0.18)
HistoGenetics Wins Multi-Year Contract for HLA Typing Using PacBio Sequencing
GlobeNewswire - Mon Aug 01, 6:30AM CDT
Pacific Biosciences of California, Inc. (NasdaqACB) today announced that HistoGenetics, a pioneer and global leader in high-resolution HLA sequence-based typing services, has received a multi-year contract to perform HLA typing using PacBio sequencing. The contract is expected to drive demand for several thousand samples per week over the next several years.
PACB: 8.28 (-0.02)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 10.91 (-5.03), PACB: 8.28 (-0.02), AVXL: 3.05 (+0.02), PPHM: 0.37 (+0.01)
What Caused Illumina's Shares to Crash 19% In April
Todd Campbell, The Motley Fool - Motley Fool - Thu May 05, 7:20AM CDT
SOURCE: ILLUMINA INC. What: After pre-announcing a revenue and profit shortfall, Illumina saw its shares lose 19.1% of their value last month, according to data from S&P Global Market Intelligence . So what: The maker of instruments...
PACB: 8.28 (-0.02), TMO: 151.18 (+0.23), ILMN: 167.90 (-0.66)
Pacific Biosciences and Advanced Analytical Technologies Announce Co-Marketing Agreement
GlobeNewswire - Tue Apr 26, 6:30AM CDT
Pacific Biosciences of California, Inc., (NasdaqACB) and Advanced Analytical Technologies, Inc., (AATI) today announced the companies have signed an agreement to jointly promote their technology solutions for long-read DNA sequencing.
PACB: 8.28 (-0.02)
Is Pacific Biosciences or Illumina Corp. a Better Buy?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 25, 7:20AM CDT
SOURCE: ILLUMINA CORP. After reporting preliminary sales figures that were south of industry watchers' forecasts, shares in gene-sequencing giant Illumina Corp. toppled this week. Meanwhile, better-than-anticipated sales at Illumina's smaller...
PACB: 8.28 (-0.02), ILMN: 167.90 (-0.66)
Why Shares of Pacific Biosciences of California Spiked 19% Today
Travis Hoium, The Motley Fool - Motley Fool - Fri Apr 22, 2:58PM CDT
The Sequel System. Image source: Pacific Biosciences. What: Shares of DNA sequencing company Pacific Biosciences of California jumped as much as 19% today after the company reported first-quarter earnings. So what: Revenue rose 8% from a...
PACB: 8.28 (-0.02)
Pacific Biosciences of California Pushing Toward Sustainable Growth
Travis Hoium, The Motley Fool - Motley Fool - Fri Apr 22, 8:20AM CDT
First-quarter 2016 earnings from gene sequencer Pacific Biosciences of California were released after the market closed on Thursday, and the company's transition to sustainable long-term viability continued. The company launched the Sequel System...
PACB: 8.28 (-0.02)
Pacific Biosciences (PACB) Q1 Loss Narrower than Expected
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 7:21AM CDT
Pacific Biosciences of California Inc. (PACB) reported a decent first-quarter 2016, thanks to the growing demand for its new Sequel system.
PACB: 8.28 (-0.02), GMED: 23.97 (+0.51), INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10)
Pacific Biosciences reports 1Q loss
Automated Insights - Thu Apr 21, 4:02PM CDT
MENLO PARK, Calif. (AP) _ Pacific Biosciences of California Inc. (PACB) on Thursday reported a loss of $19.4 million in its first quarter.
PACB: 8.28 (-0.02)
Pacific Biosciences of California, Inc. Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 21, 3:00PM CDT
Pacific Biosciences of California, Inc. (NASDAQACB) today announced financial results for its first quarter ended March 31, 2016.
PACB: 8.28 (-0.02)
Illumina's Gene Sequencers Are About to Revolutionize Healthcare
Motley Fool Staff - Motley Fool - Wed Apr 20, 7:21AM CDT
Over 7,500 of Illumina Corp 's gene sequencing machines are already being used by researchers globally to advance our understanding of DNA and DNA's relationship with disease. Discoveries stemming from this research are leading...
PACB: 8.28 (-0.02), TMO: 151.18 (+0.23), ILMN: 167.90 (-0.66)
Are Illumina's Shares Worth Buying on This Drop?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 5:21PM CDT
Image source: Illumina Inc. After the closing bell yesterday, Illumina 's management surprised investors with lackluster preliminary first-quarter sales that caused shares in the gene sequencing giant to plummet. With shares deeply discounted...
PACB: 8.28 (-0.02), TMO: 151.18 (+0.23), ILMN: 167.90 (-0.66)
Why Illumina Shares Are Tanking 18% Pre-Market
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 7:36AM CDT
SOURCE: ILLUMINA CORP What: After issuing preliminary revenue for the first quarter that was below industry watcher's targets, shares of Illumina are indicated to open lower by 18% today as of 8:30 a.m. EST. So what: The maker of machines...
PACB: 8.28 (-0.02), ILMN: 167.90 (-0.66)
What Awaits Pacific Biosciences (PACB) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 7:12AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report first-quarter 2016 results on Apr 21.
BDX: 177.32 (+0.30), PRXL: 68.70 (+0.36), PACB: 8.28 (-0.02), ALGN: 95.78 (+2.02)
Healthcare's Future: Science Fiction or Science Fact
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sat Apr 16, 11:03AM CDT
The potential to revolutionize healthcare is being driven by significant advances in technology that may improve patient procedures and usher in an era of personalized medicine. At the forefront of this innovation are Intuitive Surgica l's robotic...
ISRG: 688.37 (-1.32), PACB: 8.28 (-0.02), ILMN: 167.90 (-0.66), TRXC: 1.39 (+0.02)
Biotech Stocks on Investors' Radar -- Alexion Pharma, BioMarin Pharma, Merrimack Pharma, and Pacific Biosciences of California
PR Newswire - Wed Aug 31, 6:50AM CDT
Stock-Callers.com's focus shifted to Biotechnology industry which uses biological systems or living organisms for the development of biopharmaceutical drugs. Two main catalysts driving stocks in this arena are clinical and regulatory developments. Let us now review today's featured companies: Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), and Pacific Biosciences of California Inc. (NASDAQ: PACB). Learn more about these stocks by downloading their comprehensive and free reports at:
MACK: 4.53 (-0.06), PACB: 8.28 (-0.02), BMRN: 95.73 (+0.54), ALXN: 123.67 (-1.96)
Pacific Biosciences (PACB) Q2 Impressive, View Encourages
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 6:45AM CDT
Pacific Biosciences of California Inc. (PACB) reported a loss of 21 cents per share, a penny narrower than the Zacks Consensus Estimate.
BABY: 40.64 (+0.93), PACB: 8.28 (-0.02), MASI: 59.90 (+0.47), MLAB: 112.17 (-1.21)
Pacific Biosciences Releases New Software and Chemistry for Sequel System
GlobeNewswire - Thu Aug 04, 3:14PM CDT
Pacific Biosciences of California, Inc. (Nasdaq
ACB) today announced it has released a set of key updates for the Sequel(TM) System, the company's latest product based on its Single Molecule, Real-Time (SMRT) Sequencing technology. The new release provides performance improvements via updated sequencing chemistry, optimized sample clean-up protocols, and associated software that together further improve read lengths, throughput and accuracy of the system. In addition, as customers upgrade their Sequel Systems to the new software and chemistry, they will no longer be subject to the supply constraints for SMRT Cells that were in effect earlier this year. PACB: 8.28 (-0.02)
Pacific Biosciences of California, Inc. Announces Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 04, 3:00PM CDT
Pacific Biosciences of California, Inc. (NASDAQ
ACB) today announced financial results for its second quarter ended June 30, 2016. PACB: 8.28 (-0.02)
Pacific Biosciences (PACB) Q2 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 8:52AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report second-quarter 2016 results on Aug 4.
ZTS: 51.26 (+0.15), PACB: 8.28 (-0.02), ANIP: 59.86 (-1.56), GLYC: 7.25 (-0.18)
HistoGenetics Wins Multi-Year Contract for HLA Typing Using PacBio Sequencing
GlobeNewswire - Mon Aug 01, 6:30AM CDT
Pacific Biosciences of California, Inc. (Nasdaq
ACB) today announced that HistoGenetics, a pioneer and global leader in high-resolution HLA sequence-based typing services, has received a multi-year contract to perform HLA typing using PacBio sequencing. The contract is expected to drive demand for several thousand samples per week over the next several years. PACB: 8.28 (-0.02)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 10.91 (-5.03), PACB: 8.28 (-0.02), AVXL: 3.05 (+0.02), PPHM: 0.37 (+0.01)
What Caused Illumina's Shares to Crash 19% In April
Todd Campbell, The Motley Fool - Motley Fool - Thu May 05, 7:20AM CDT
SOURCE: ILLUMINA INC. What: After pre-announcing a revenue and profit shortfall, Illumina saw its shares lose 19.1% of their value last month, according to data from S&P Global Market Intelligence . So what: The maker of instruments...
PACB: 8.28 (-0.02), TMO: 151.18 (+0.23), ILMN: 167.90 (-0.66)
Pacific Biosciences and Advanced Analytical Technologies Announce Co-Marketing Agreement
GlobeNewswire - Tue Apr 26, 6:30AM CDT
Pacific Biosciences of California, Inc., (Nasdaq
ACB) and Advanced Analytical Technologies, Inc., (AATI) today announced the companies have signed an agreement to jointly promote their technology solutions for long-read DNA sequencing. PACB: 8.28 (-0.02)
Is Pacific Biosciences or Illumina Corp. a Better Buy?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 25, 7:20AM CDT
SOURCE: ILLUMINA CORP. After reporting preliminary sales figures that were south of industry watchers' forecasts, shares in gene-sequencing giant Illumina Corp. toppled this week. Meanwhile, better-than-anticipated sales at Illumina's smaller...
PACB: 8.28 (-0.02), ILMN: 167.90 (-0.66)
Why Shares of Pacific Biosciences of California Spiked 19% Today
Travis Hoium, The Motley Fool - Motley Fool - Fri Apr 22, 2:58PM CDT
The Sequel System. Image source: Pacific Biosciences. What: Shares of DNA sequencing company Pacific Biosciences of California jumped as much as 19% today after the company reported first-quarter earnings. So what: Revenue rose 8% from a...
PACB: 8.28 (-0.02)
Pacific Biosciences of California Pushing Toward Sustainable Growth
Travis Hoium, The Motley Fool - Motley Fool - Fri Apr 22, 8:20AM CDT
First-quarter 2016 earnings from gene sequencer Pacific Biosciences of California were released after the market closed on Thursday, and the company's transition to sustainable long-term viability continued. The company launched the Sequel System...
PACB: 8.28 (-0.02)
Pacific Biosciences (PACB) Q1 Loss Narrower than Expected
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 7:21AM CDT
Pacific Biosciences of California Inc. (PACB) reported a decent first-quarter 2016, thanks to the growing demand for its new Sequel system.
PACB: 8.28 (-0.02), GMED: 23.97 (+0.51), INGN: 58.11 (+0.16), EXAC: 27.90 (+0.10)
Pacific Biosciences reports 1Q loss
Automated Insights - Thu Apr 21, 4:02PM CDT
MENLO PARK, Calif. (AP) _ Pacific Biosciences of California Inc. (PACB) on Thursday reported a loss of $19.4 million in its first quarter.
PACB: 8.28 (-0.02)
Pacific Biosciences of California, Inc. Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 21, 3:00PM CDT
Pacific Biosciences of California, Inc. (NASDAQ
ACB) today announced financial results for its first quarter ended March 31, 2016. PACB: 8.28 (-0.02)
Illumina's Gene Sequencers Are About to Revolutionize Healthcare
Motley Fool Staff - Motley Fool - Wed Apr 20, 7:21AM CDT
Over 7,500 of Illumina Corp 's gene sequencing machines are already being used by researchers globally to advance our understanding of DNA and DNA's relationship with disease. Discoveries stemming from this research are leading...
PACB: 8.28 (-0.02), TMO: 151.18 (+0.23), ILMN: 167.90 (-0.66)
Are Illumina's Shares Worth Buying on This Drop?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 5:21PM CDT
Image source: Illumina Inc. After the closing bell yesterday, Illumina 's management surprised investors with lackluster preliminary first-quarter sales that caused shares in the gene sequencing giant to plummet. With shares deeply discounted...
PACB: 8.28 (-0.02), TMO: 151.18 (+0.23), ILMN: 167.90 (-0.66)
Why Illumina Shares Are Tanking 18% Pre-Market
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 7:36AM CDT
SOURCE: ILLUMINA CORP What: After issuing preliminary revenue for the first quarter that was below industry watcher's targets, shares of Illumina are indicated to open lower by 18% today as of 8:30 a.m. EST. So what: The maker of machines...
PACB: 8.28 (-0.02), ILMN: 167.90 (-0.66)
What Awaits Pacific Biosciences (PACB) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 7:12AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report first-quarter 2016 results on Apr 21.
BDX: 177.32 (+0.30), PRXL: 68.70 (+0.36), PACB: 8.28 (-0.02), ALGN: 95.78 (+2.02)
Healthcare's Future: Science Fiction or Science Fact
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sat Apr 16, 11:03AM CDT
The potential to revolutionize healthcare is being driven by significant advances in technology that may improve patient procedures and usher in an era of personalized medicine. At the forefront of this innovation are Intuitive Surgica l's robotic...
ISRG: 688.37 (-1.32), PACB: 8.28 (-0.02), ILMN: 167.90 (-0.66), TRXC: 1.39 (+0.02)
(0)
(0)Scroll down for more posts ▼